In the last trading session, 1.03 million shares of the Axsome Therapeutics Inc. (NASDAQ:AXSM) were traded, and its beta was 2.18. Most recently the company’s share price was $35.80, and it changed around $0.21 or 0.59% from the last close, which brings the market valuation of the company to $1.34B. AXSM currently trades at a discount to its 52-week high of $87.24, offering almost -143.69% off that amount. The share price’s 52-week low was $19.38, which indicates that the current value has risen by an impressive 45.87% since then. We note from Axsome Therapeutics Inc.’s average daily trading volume that its 3-month average coming to 1.15 million.
Axsome Therapeutics Inc. stock received a consensus recommendation rating of a Buy, based on a mean score of 1.90. If we narrow it down even further, the data shows that 0 out of 15 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 2 recommended AXSM as a Hold, whereas 12 deemed it a Buy, and 1 rated it as Underweight. Axsome Therapeutics Inc. is expected to report earnings per share of -$0.95 for the current quarter.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Instantly AXSM has showed a green trend with a performance of 0.59% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 39.36 on Friday, 11/19/21 increased the stock’s daily price by 9.04%. The company’s shares are currently down -56.06% year-to-date, but still down -8.81% over the last five days. On the other hand, Axsome Therapeutics Inc. (NASDAQ:AXSM) is -12.30% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $86.20, which translates to bulls needing to increase their stock price by 58.47% from its current value. Analyst projections state that AXSM is forecast to be at a low of $26.00 and a high of $180.00. In order for the stock price to hit the forecast high, the stock would need to plunge -402.79% from its current level, while the stock would need to crash 27.37% from its current level to reach the projected low.
Axsome Therapeutics Inc. (AXSM) estimates and forecasts
Moreover, analysts have decided to roll up on their fiscal year 2021 revenue estimates. The rating firms predict that it will loss -55.70% in revenue this quarter, and will report a decrease of -32.10% in the next quarter.
11 analysts expect Axsome Therapeutics Inc. to make $60k in revenue for the quarter ending Dec 2021.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -22.00%.
Axsome Therapeutics Inc.’s next quarterly earnings report is expected to be released around November 03 and November 08.
Axsome Therapeutics Inc. (NASDAQ:AXSM)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 21.40% of Axsome Therapeutics Inc. shares, and 61.32% of them are in the hands of institutional investors. The stock currently has a share float of 78.01%. Axsome Therapeutics Inc. stock is held by 257 institutions, with Vanguard Group, Inc. (The) being the largest institutional investor. By Jun 29, 2021, it held 6.94% of the shares, which is about 2.61 million shares worth $176.35 million.
Iridian Asset Management LLC, with 6.14% or 2.32 million shares worth $156.19 million as of Jun 29, 2021, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund were the top two Mutual Funds as of Jun 29, 2021. The former held 0.8 million shares worth $53.64 million, making up 2.11% of all outstanding shares. On the other hand, Vanguard Small-Cap Index Fund held roughly 0.7 million shares worth around $47.42 million, which represents about 1.87% of the total shares outstanding.